What Is Necrotizing Pancreatitis and How Is It Treated?

Necrotizing pancreatitis is a severe form of acute pancreatitis in which portions of the pancreas, the surrounding fat, or both die off due to disrupted blood supply and runaway inflammation. It develops in roughly 10 to 20 percent of people hospitalized with acute pancreatitis, and it carries substantially higher risks of organ failure, infection, and death than milder forms of the disease. Treatment has shifted dramatically over the past two decades, moving from early open surgery toward a more measured strategy that starts with supportive care and escalates only when necessary.

Why the Pancreas Starts to Die

Acute pancreatitis begins when digestive enzymes activate inside the pancreas instead of in the small intestine. In most cases, the resulting inflammation resolves on its own. In necrotizing pancreatitis, the inflammatory cascade is severe enough to cut off local blood flow, starving tissue of oxygen. The damaged cells then undergo necrosis, a form of uncontrolled cell death that spills their contents into surrounding tissue and amplifies inflammation further. Research in animal models has shown that the balance between different forms of cell death matters: when cells die through apoptosis (a more orderly, self-contained process), the pancreas fares better, but when apoptotic pathways are blocked, necrosis increases dramatically.¹ This helps explain why some episodes of pancreatitis remain mild while others spiral into tissue death.

The causes mirror those of acute pancreatitis in general. Gallstones are the most common trigger in the United States, followed by heavy alcohol use. Less frequent causes include very high triglyceride levels, elevated calcium, certain medications, and autoimmune conditions.² Some studies have suggested alcohol-related pancreatitis is more likely to progress to necrosis, but that link has not been firmly established.²

How Necrotizing Pancreatitis Is Diagnosed

A contrast-enhanced CT scan is the standard tool for identifying dead pancreatic tissue. Healthy pancreas lights up when contrast dye is injected; necrotic areas do not, appearing as dark, non-enhancing patches. There is an important timing caveat, though: a CT scan done in the first 72 hours of symptoms can miss necrosis because the tissue damage has not yet fully declared itself. Scans are more accurate when performed at least three days after symptom onset.³ For this reason, early CT is useful for confirming pancreatitis and ruling out other emergencies, but doctors often wait before using it specifically to assess necrosis.

Blood markers also help predict who is heading toward necrosis. C-reactive protein (CRP), a general marker of inflammation, performs well at identifying patients developing necrosis. Studies have found that a CRP level above about 150 mg/L correlates significantly with the later appearance of necrosis on CT.⁴ Other markers, including lactate dehydrogenase (LDH), have also shown promise, though no single blood test is definitive on its own.⁵ These tests matter because early identification allows closer monitoring and faster ICU transfer when needed.

Detecting Infection in the Necrosis

Not all necrosis becomes infected, but infected necrosis is the main driver of complications and death. The challenge is that clinical signs of infection, such as fever, elevated white blood cell counts, and other markers of systemic inflammation, look nearly identical whether the necrosis is sterile or infected.⁶ Gas bubbles within the necrotic collection on CT are a strong indicator of infection, but they are not always present. When the clinical picture is unclear, doctors may perform a fine-needle aspiration, using ultrasound or CT guidance to insert a thin needle into the necrotic area and test the fluid for bacteria. In many centers, however, the decision to treat for infection now relies more on clinical trajectory and imaging findings than on routine needle aspiration.

Early Medical Management

The first days of treatment focus on aggressive supportive care rather than any attempt to remove dead tissue. Three pillars dominate early management: intravenous fluids, nutritional support, and careful decisions about antibiotics.

Fluid Resuscitation

Patients with severe pancreatitis lose large volumes of fluid into inflamed tissues and the abdominal cavity. Replacing that fluid promptly is one of the few interventions that clearly improves outcomes. A systematic review of randomized trials found that using lactated Ringer’s solution rather than normal saline reduced the risk of organ failure, the need for intensive care, and the rate of local complications.⁷ The same analysis estimated a roughly 60 percent reduction in the risk of death with lactated Ringer’s, though the authors noted that the quality of the mortality evidence was low. Still, the overall signal has been strong enough that lactated Ringer’s has become the preferred resuscitation fluid for pancreatitis in most guidelines.

Nutrition

The old practice of putting the gut to complete rest and feeding patients intravenously has largely been abandoned. Comparative trials have shown that enteral feeding through a tube placed into the small intestine is safer and better tolerated than intravenous nutrition for most patients with acute pancreatitis, including severe cases.⁸ Enteral feeding maintains gut barrier function, which may reduce the risk of bacteria migrating from the intestines into the necrotic pancreatic tissue. There may be exceptions, however: patients with damage to the pancreatic duct system from necrotizing disease may experience complications with enteral feeding, and in those cases, intravenous nutrition and pancreatic rest may be the safer route.⁸

The Antibiotics Debate

Few topics in pancreatitis management have generated as much back-and-forth as whether patients with necrotizing pancreatitis should receive preventive antibiotics before any infection is proven. The reasoning sounds intuitive: dead tissue is a perfect breeding ground for bacteria, so getting ahead of infection with antibiotics should help. The evidence, however, has not cooperated neatly.

One meta-analysis of randomized trials found that early preventive antibiotics reduced the rate of infected necrosis, with infection developing in about 16 percent of treated patients compared to 25 percent of controls.⁹ A separate meta-analysis, however, reached the opposite conclusion, finding that rates of infected necrosis and mortality were not significantly different between antibiotic and control groups.¹⁰ Data from at least one center even suggested harm from routine antibiotic use: mortality was significantly higher in patients given prophylactic antibiotics (9 percent) than in those who were not treated (0 percent), and morbidity was also substantially higher in the antibiotic group.¹¹

The concern with blanket antibiotic use is that it can select for resistant organisms, particularly fungi, which are harder to treat and associated with worse outcomes. Most current guidelines therefore do not recommend routine preventive antibiotics for necrotizing pancreatitis. Antibiotics are reserved for confirmed or strongly suspected infection, and the choice of drug is guided by culture results whenever possible.

When Dead Tissue Needs to Come Out

Sterile necrosis is generally managed without intervention. Even large collections of dead tissue can be observed and allowed to organize over weeks, as long as the patient is stable. The trigger for active intervention is typically infected necrosis, which develops in a subset of patients, usually at least two to three weeks into the illness. Signs include persistent or new fever, worsening organ function, and sometimes gas within the necrotic collection on imaging.

The timing of that intervention matters. A randomized trial compared immediate drainage for infected necrosis against a strategy of postponing drainage and treating with antibiotics alone first. In the postponed group, about 39 percent of patients never required drainage at all and recovered on antibiotics, and 17 of those 19 patients survived. The postponed group also needed fewer total procedures on average.¹² This trial reinforced the idea that even when infection is confirmed, there is often room to let antibiotics work before escalating to invasive procedures.

The Step-Up Approach

The most significant shift in the treatment of necrotizing pancreatitis over the past two decades has been the move away from early open surgery and toward what is known as the step-up approach. Historically, infected necrosis was treated with open necrosectomy: a major abdominal operation in which surgeons physically removed dead tissue. That procedure, while sometimes lifesaving, carried staggering complication rates, with morbidity reported between 34 and 95 percent and mortality between 11 and 39 percent.¹³

The step-up approach starts with the least invasive option and escalates only if the patient does not improve. The first step is typically percutaneous catheter drainage, in which a radiologist places a tube through the skin into the fluid collection to drain it. If drainage alone is insufficient, the next step is a minimally invasive procedure to physically remove solid necrotic debris. One such technique is video-assisted retroperitoneal debridement (VARD), in which a small incision is made in the flank and a camera is used to guide the removal of dead tissue from behind the abdominal cavity.¹⁴ In cases that remain refractory even after VARD, additional rounds of endoscopic debridement through the drainage tract may be attempted.¹⁵

The landmark trial comparing this strategy to open necrosectomy was published in the New England Journal of Medicine. The composite endpoint of major complications or death occurred in about 40 percent of patients randomized to the step-up approach, compared to 69 percent with open necrosectomy. New-onset organ failure was three times more common after open surgery. About 35 percent of patients in the step-up group were managed with drainage alone and never needed surgical debridement at all.¹⁶ Subsequent case-matched analyses have confirmed lower morbidity and lower rates of pancreatic insufficiency with the step-up approach.¹⁷

Endoscopic Versus Surgical Step-Up

Within the step-up framework, there is a further choice: should the escalation go through an endoscopic route (through the stomach wall, using an endoscope) or a surgical route (through the skin and retroperitoneum)? Endoscopic drainage and debridement use a flexible scope passed through the mouth and stomach, with a stent placed through the stomach wall directly into the necrotic collection. Lumen-apposing metal stents have become the standard tool for this approach.¹⁸

A randomized trial with seven years of follow-up compared the endoscopic and surgical step-up pathways head to head. The rate of major complications or death was similar between the two approaches, at about 53 percent with endoscopy and 57 percent with surgery over that long follow-up period. The endoscopic route, however, had two distinct advantages: far fewer patients developed pancreaticocutaneous fistulas (abnormal connections between the pancreas and the skin), and patients in the endoscopy group needed fewer reinterventions after the initial treatment period.¹⁹ Pancreatic function and quality of life were comparable between the groups. The practical implication is that in centers with expertise in both techniques, the endoscopic route is increasingly preferred as the first-line escalation step, though the surgical route remains essential for cases where anatomy or collection location makes endoscopic access difficult.

Long-Term Consequences After Recovery

Surviving necrotizing pancreatitis is not the end of the story. The destruction of pancreatic tissue can permanently impair the organ’s ability to produce digestive enzymes and insulin, leading to problems that persist for years.

A prospective study of patients at six months after necrotizing pancreatitis found exocrine insufficiency, meaning the pancreas could no longer produce enough digestive enzymes, in 40 percent of patients. Endocrine dysfunction, affecting blood sugar regulation, was present in 30 percent.²⁰ A larger study following 390 patients found that new-onset diabetes developed in about a quarter of them, typically appearing within the first year. Among those who developed diabetes, 84 percent required insulin, and 69 percent also had exocrine insufficiency.²¹ Visceral fat, the fat stored deep around the abdominal organs, was identified as a predictor of which patients would go on to develop diabetes.

Exocrine insufficiency shows up as bloating, fatty stools, and unintentional weight loss because food is no longer being properly broken down and absorbed. It is managed with pancreatic enzyme replacement therapy, taken with meals. The diabetes that follows necrotizing pancreatitis tends to be more difficult to manage than typical type 2 diabetes because it stems from actual destruction of insulin-producing cells rather than insulin resistance, which means insulin therapy is often needed from the start.

Long-term follow-up data from the original step-up versus open necrosectomy trial confirmed that outcomes continued to favor the less invasive approach years later: about 44 percent of patients in the step-up group experienced death or major complications by long-term follow-up, compared to 73 percent in the open surgery group.²² Quality of life improved over time in both groups without a significant difference between them, suggesting that while the step-up approach spares patients early complications, survivors ultimately reach a similar baseline regardless of which path they took.

Vascular Complications

One of the less well-known dangers of necrotizing pancreatitis is its ability to damage nearby blood vessels. The enzymes and inflammatory mediators released by dying pancreatic tissue can erode into arterial walls, leading to pseudoaneurysms, which are essentially contained ruptures of the vessel. When these burst, the bleeding can be life-threatening. Pseudoaneurysms most commonly involve the splenic artery, but they can appear in less typical locations as well. A case report documented a patient with necrotizing pancreatitis who developed multiple pseudoaneurysms in the hepatic arteries, a rare presentation that illustrates how far-reaching the vascular injury from pancreatic necrosis can be.²³ Interventional radiologists treat these by threading a catheter into the bleeding vessel and blocking it with coils or other embolic agents. Awareness of this complication matters because a sudden drop in blood counts or a spike in pain during the recovery phase should prompt immediate vascular imaging.

How Treatment Philosophy Has Changed

Looking at the arc of necrotizing pancreatitis management over the past few decades reveals a consistent theme: restraint has replaced aggression at almost every decision point. Early open surgery gave way to the step-up approach. Routine preventive antibiotics gave way to targeted use for confirmed infection. Immediate drainage gave way to a trial of antibiotics first. Surgical debridement gave way to endoscopic techniques. The thread connecting these changes is a recognition that the inflamed, necrotic pancreas tolerates intervention poorly, and that giving the body more time to wall off the damage and organize the necrotic collection before acting tends to produce better outcomes.²⁴

This shift has not come easily. Necrotizing pancreatitis still kills roughly one in five patients who develop infected necrosis, even with current best practices.¹⁶ Organ failure in the first week remains the leading cause of early death, and late deaths are driven by infected necrosis and the complications of intervention. What has changed is that the treatments themselves now cause less collateral damage, giving patients a better chance of emerging with functioning organs and an intact quality of life.